PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7344909

Caffeine: an update.

B L Oser·R A Ford
View original source ↗Export metadata ↓

Abstract

While the total annual volume of caffeine has increased over the years, the actual per capita daily intake has not. This is based on the fact that the quantity of caffeine in a soft drink is about the same or, in the case of diet drinks, less than in 1961 when the original GRAS (Generally Recognized as Safe) determinations were made. Since that time, there have been numerous studies on the effect of caffeine on animals and humans. The Select Committee on GRAS Substances (SCOGS) of the Federation of American Societies for Experimental Biology (FASEB) in 1978 reviewed all the data available at that time and concluded that there is "no evidence in the available information on caffeine [that] demonstrates a hazard to the public when it is used in cola-type beverages at levels that are now current and in the manner now practiced...", although they did suggest further study was necessary. The Flavor and Extract Manufacturers' Association (FEMA) Expert Panel has now reviewed not only the same data s the FASEB (SCOGS) Committee, but several more recent studies. On the basis of this review, the Panel reaffirms the GRAS status of caffeine under conditions of its current use as an international ingredient in nonalcoholic beverages.

Explore related subjects

Abnormalities, Drug-InducedAdolescentAdultAnimalsBehaviorCaffeineChildChild, PreschoolFemaleHumansInfantInfant, NewbornKineticsMiceMiddle AgedNeoplasmsPregnancyRatsReproductionJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B L Oser, R A Ford. 1981. Caffeine: an update.. https://doi.org/10.3109/01480548109017824

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Pregnancy in Parkinson's disease: a review of the literature and a case report.

Pregnancy is rare in Parkinson's disease (PD). In the literature on studies of antiparkinsonian drugs in animals during pregnancy, there are reports on malformations of the skeletal and circulatory system. However, the majority of studies in animals have not shown any teratogenicity. Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline. The published experience with humans consists of 35 pregnancies among 26 women suffering from PD, including this report, and a number of cases treated with antiparkinsonian agents for other reasons. With the exception of the majority of the cases where amantadine was used, complications have been rare. However, there are indications that suggest a possible risk of a woman's parkinsonism worsening in connection with pregnancy. We also report the case of a woman with PD who was treated with L-dopa-benserazide during an uncomplicated pregnancy and gave birth to a healthy boy without experiencing any worsening of her PD.

Abnormalities, Drug-Induced↗
PubMed1998

Dextromethorphan and other N-methyl-D-aspartate receptor antagonists are teratogenic in the avian embryo model.

N-Methyl-D-aspartate (NMDA) receptors are a calcium-conducting class of excitatory amino acid receptors that are involved in neuronal development and migration. Certain well known teratogens (e.g. homocysteine, ethanol, and chloroform) that induce congenital neural tube and neural crest defects also have the capacity to act as NMDA receptor antagonists. We hypothesized that teratogenicity was a general property of NMDA receptor antagonists, and that high affinity NMDA receptor antagonists would induce neural tube and neural crest defects. Chicken embryos were given 5, 50, or 500 nmol/d of selected NMDA receptor antagonists for 3 consecutive days during the process of neural tube closure, beginning 4 h after the beginning of incubation. Selected NMDA receptor antagonists represented three classes of antagonists: ion channel blockers, glycine site antagonists, and glutamate site agonists and antagonists. All classes of NMDA receptor antagonists induced embryonic death and congenital defects of the neural crest and neural tube; however, the channel blockers were the most potent teratogens. Dextromethorphan at 500 nmol/embryo/d killed more than half the embryos and induced congenital defects in about one-eighth of the survivors; dextromethorphan was also highly lethal at 50 nmol/embryo/d. Glutamate site NMDA receptor agonists (NMDA and homoquinolinic acid) displayed weak toxicity relative to their known NMDA receptor potency. Taken together, these data indicate that NMDA receptor antagonists, particularly channel blockers, are potent teratogens in the chicken embryo model. Because dextromethorphan is a widely used nonprescription antitussive, its strong teratogeneticity using this model is particularly noteworthy.

Abnormalities, Drug-Induced↗